Psychosine, a marker of Krabbe phenotype and treatment effect

M. L. Escolar, B. T. Kiely, E. Shawgo, X. Hong, M. H. Gelb, J. J. Orsini, D. Matern, M. D. Poe

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Newborn screening (NBS) for Krabbe disease, a rare neurodegenerative disorder caused by deficient galactocerebrosidase (GALC) enzyme activity, has recently been implemented in a number of US states. However, the spectrum of phenotypic manifestations associated with deficient GALC activity complicates the management of screen-positive newborns and underscores the need to identify clinically relevant biomarkers. Earlier studies with a small number of patients identified psychosine, a substrate of the GALC enzyme, as a potential biomarker for Krabbe disease. In this study, we provide, for the first time, longitudinal data on dried blood spot (DBS) psychosine concentrations in different Krabbe disease phenotypes for both untreated patients and those treated with hematopoietic stem cell transplantation (HSCT). Our cohort included patients previously identified by NBS to be at high risk to develop Krabbe disease. Substantially elevated DBS psychosine concentration during the newborn period was found to be a highly specific marker for infantile Krabbe disease. This finding supports the use of DBS psychosine concentration as a second-tier NBS test to aid in the identification of patients who require urgent evaluation for HSCT. In addition, longitudinal assessments showed that both natural disease progression and treatment with HSCT were associated with decreases in DBS psychosine concentrations. Based on these findings we provide recommendations for the interpretation of psychosine concentrations in DBS specimens collected during the first year of life. Future studies should aim to better delineate the relationship between DBS psychosine concentration and disease onset in patients with later-onset forms of Krabbe disease.

Original languageEnglish (US)
Pages (from-to)271-278
Number of pages8
JournalMolecular Genetics and Metabolism
Volume121
Issue number3
DOIs
StatePublished - Jul 1 2017

Fingerprint

Psychosine
Globoid Cell Leukodystrophy
Galactosylceramidase
Phenotype
Blood
Newborn Infant
Hematopoietic Stem Cell Transplantation
Stem cells
Screening
Biomarkers
Therapeutics
Enzymes
Neurodegenerative Diseases
Enzyme activity
Disease Progression

Keywords

  • Galactosylsphingosine
  • Globoid cell leukodystrophy
  • Krabbe disease
  • Newborn screening
  • Psychosine
  • Tandem mass spectrometry

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Biology
  • Genetics
  • Endocrinology

Cite this

Escolar, M. L., Kiely, B. T., Shawgo, E., Hong, X., Gelb, M. H., Orsini, J. J., ... Poe, M. D. (2017). Psychosine, a marker of Krabbe phenotype and treatment effect. Molecular Genetics and Metabolism, 121(3), 271-278. https://doi.org/10.1016/j.ymgme.2017.05.015

Psychosine, a marker of Krabbe phenotype and treatment effect. / Escolar, M. L.; Kiely, B. T.; Shawgo, E.; Hong, X.; Gelb, M. H.; Orsini, J. J.; Matern, D.; Poe, M. D.

In: Molecular Genetics and Metabolism, Vol. 121, No. 3, 01.07.2017, p. 271-278.

Research output: Contribution to journalArticle

Escolar, ML, Kiely, BT, Shawgo, E, Hong, X, Gelb, MH, Orsini, JJ, Matern, D & Poe, MD 2017, 'Psychosine, a marker of Krabbe phenotype and treatment effect', Molecular Genetics and Metabolism, vol. 121, no. 3, pp. 271-278. https://doi.org/10.1016/j.ymgme.2017.05.015
Escolar ML, Kiely BT, Shawgo E, Hong X, Gelb MH, Orsini JJ et al. Psychosine, a marker of Krabbe phenotype and treatment effect. Molecular Genetics and Metabolism. 2017 Jul 1;121(3):271-278. https://doi.org/10.1016/j.ymgme.2017.05.015
Escolar, M. L. ; Kiely, B. T. ; Shawgo, E. ; Hong, X. ; Gelb, M. H. ; Orsini, J. J. ; Matern, D. ; Poe, M. D. / Psychosine, a marker of Krabbe phenotype and treatment effect. In: Molecular Genetics and Metabolism. 2017 ; Vol. 121, No. 3. pp. 271-278.
@article{ec3730b1859b4b788495267f9e46e548,
title = "Psychosine, a marker of Krabbe phenotype and treatment effect",
abstract = "Newborn screening (NBS) for Krabbe disease, a rare neurodegenerative disorder caused by deficient galactocerebrosidase (GALC) enzyme activity, has recently been implemented in a number of US states. However, the spectrum of phenotypic manifestations associated with deficient GALC activity complicates the management of screen-positive newborns and underscores the need to identify clinically relevant biomarkers. Earlier studies with a small number of patients identified psychosine, a substrate of the GALC enzyme, as a potential biomarker for Krabbe disease. In this study, we provide, for the first time, longitudinal data on dried blood spot (DBS) psychosine concentrations in different Krabbe disease phenotypes for both untreated patients and those treated with hematopoietic stem cell transplantation (HSCT). Our cohort included patients previously identified by NBS to be at high risk to develop Krabbe disease. Substantially elevated DBS psychosine concentration during the newborn period was found to be a highly specific marker for infantile Krabbe disease. This finding supports the use of DBS psychosine concentration as a second-tier NBS test to aid in the identification of patients who require urgent evaluation for HSCT. In addition, longitudinal assessments showed that both natural disease progression and treatment with HSCT were associated with decreases in DBS psychosine concentrations. Based on these findings we provide recommendations for the interpretation of psychosine concentrations in DBS specimens collected during the first year of life. Future studies should aim to better delineate the relationship between DBS psychosine concentration and disease onset in patients with later-onset forms of Krabbe disease.",
keywords = "Galactosylsphingosine, Globoid cell leukodystrophy, Krabbe disease, Newborn screening, Psychosine, Tandem mass spectrometry",
author = "Escolar, {M. L.} and Kiely, {B. T.} and E. Shawgo and X. Hong and Gelb, {M. H.} and Orsini, {J. J.} and D. Matern and Poe, {M. D.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.ymgme.2017.05.015",
language = "English (US)",
volume = "121",
pages = "271--278",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Psychosine, a marker of Krabbe phenotype and treatment effect

AU - Escolar, M. L.

AU - Kiely, B. T.

AU - Shawgo, E.

AU - Hong, X.

AU - Gelb, M. H.

AU - Orsini, J. J.

AU - Matern, D.

AU - Poe, M. D.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Newborn screening (NBS) for Krabbe disease, a rare neurodegenerative disorder caused by deficient galactocerebrosidase (GALC) enzyme activity, has recently been implemented in a number of US states. However, the spectrum of phenotypic manifestations associated with deficient GALC activity complicates the management of screen-positive newborns and underscores the need to identify clinically relevant biomarkers. Earlier studies with a small number of patients identified psychosine, a substrate of the GALC enzyme, as a potential biomarker for Krabbe disease. In this study, we provide, for the first time, longitudinal data on dried blood spot (DBS) psychosine concentrations in different Krabbe disease phenotypes for both untreated patients and those treated with hematopoietic stem cell transplantation (HSCT). Our cohort included patients previously identified by NBS to be at high risk to develop Krabbe disease. Substantially elevated DBS psychosine concentration during the newborn period was found to be a highly specific marker for infantile Krabbe disease. This finding supports the use of DBS psychosine concentration as a second-tier NBS test to aid in the identification of patients who require urgent evaluation for HSCT. In addition, longitudinal assessments showed that both natural disease progression and treatment with HSCT were associated with decreases in DBS psychosine concentrations. Based on these findings we provide recommendations for the interpretation of psychosine concentrations in DBS specimens collected during the first year of life. Future studies should aim to better delineate the relationship between DBS psychosine concentration and disease onset in patients with later-onset forms of Krabbe disease.

AB - Newborn screening (NBS) for Krabbe disease, a rare neurodegenerative disorder caused by deficient galactocerebrosidase (GALC) enzyme activity, has recently been implemented in a number of US states. However, the spectrum of phenotypic manifestations associated with deficient GALC activity complicates the management of screen-positive newborns and underscores the need to identify clinically relevant biomarkers. Earlier studies with a small number of patients identified psychosine, a substrate of the GALC enzyme, as a potential biomarker for Krabbe disease. In this study, we provide, for the first time, longitudinal data on dried blood spot (DBS) psychosine concentrations in different Krabbe disease phenotypes for both untreated patients and those treated with hematopoietic stem cell transplantation (HSCT). Our cohort included patients previously identified by NBS to be at high risk to develop Krabbe disease. Substantially elevated DBS psychosine concentration during the newborn period was found to be a highly specific marker for infantile Krabbe disease. This finding supports the use of DBS psychosine concentration as a second-tier NBS test to aid in the identification of patients who require urgent evaluation for HSCT. In addition, longitudinal assessments showed that both natural disease progression and treatment with HSCT were associated with decreases in DBS psychosine concentrations. Based on these findings we provide recommendations for the interpretation of psychosine concentrations in DBS specimens collected during the first year of life. Future studies should aim to better delineate the relationship between DBS psychosine concentration and disease onset in patients with later-onset forms of Krabbe disease.

KW - Galactosylsphingosine

KW - Globoid cell leukodystrophy

KW - Krabbe disease

KW - Newborn screening

KW - Psychosine

KW - Tandem mass spectrometry

UR - http://www.scopus.com/inward/record.url?scp=85020030476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020030476&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2017.05.015

DO - 10.1016/j.ymgme.2017.05.015

M3 - Article

VL - 121

SP - 271

EP - 278

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 3

ER -